Approved gene therapies by indication, 2026 mid-year reference

Reference layout of approved in vivo and ex vivo gene therapies as of mid-2026. Includes indication, mechanism, delivery vector or platform, regulatory pathway, and the live commercial question for each. The approved gene therapy class is now broad enough to require an organised reference; the question has moved from whether gene therapy is real to where in the patient journey each approved therapy fits. Updated quarterly as approvals and label expansions land.